Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Oct;36(5):450-4.
doi: 10.1097/COC.0b013e3182546a91.

Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma

Stephen L Richey  1 , Pheroze Tamboli, Chaan S Ng, E Lin, Zita D Lim, John C Araujo, Eric Jonasch, Padmanee Sharma, Lance C Pagliaro, Nizar M Tannir
Affiliations
Clinical Trial

Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma

Stephen L Richey et al. Am J Clin Oncol. 2013 Oct.

Abstract

Objective: To determine the clinical activity and safety of the combination of pemetrexed and gemcitabine in advanced nonclear cell renal cell carcinoma (nccRCC).

Methods: In this phase II study, patients received pemetrexed 500 mg/m intravenous infusion over 10 minutes on day 1 followed immediately by gemcitabine 1500 mg/m intravenously over 30 minutes on day 1, with cycles repeated every 14 days. Planned enrollment was 40 patients. The primary endpoints were objective response rate and progression-free survival (PFS). The secondary endpoints were safety and overall survival.

Results: Between December 2005 and December 2008, 16 patients with locally advanced or metastatic nccRCC were enrolled. The trial was stopped early due to low efficacy and excessive toxicity. The objective response rate was 0% [95% confidence interval (CI), 0%-18%]. The median number of cycles administered was 4 (range, 1 to 12). Median PFS was 3.2 months (95% CI, 1.9-6+), and the 16-week PFS rate was 46.7% (95% CI, 19.8%-100%). Median overall survival was 23.2 months (95% CI, 12.9-38.1). The most common grade 3 or 4 adverse events were neutropenia (53%), leukopenia (53%), anemia (13%), fatigue (40%), and renal insufficiency (13%).

Conclusions: In this phase II trial in nccRCC, the combination of pemetrexed and gemcitabine was toxic and ineffective. Further development of this regimen in nccRCC is not warranted.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Waterfall plot of best response
Figure 2
Figure 2
Kaplan-Meier estimate of progression free survival
Figure 3
Figure 3
Kaplan-Meier estimate of overall survival
See this image and copyright information in PMC

References

    1. Society AC. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society; American Cancer Society; 2009. http://www.cancer.org/acs/groups/content/@nho/documents/document/500809w....
    1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England journal of medicine. 2007 Jan 11;356(2):115–24. - PubMed
    1. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug 1;27(22):3584–90. - PMC - PubMed
    1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. The New England journal of medicine. 2007 Jan 11;356(2):125–34. - PubMed
    1. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 9;372(9637):449–56. - PubMed

Publication types

MeSH terms